Back

What is the evidence for empagliflozin in HF?

22 May 2022 (15:00 - 15:10)
Organised by:
Congress Presentation Part of: A new era for HFpEF – Exploring the role of empagliflozin in practice Chronic Heart Failure Open Access Heart Failure 2022

About the speaker

Photo
Professor Javed Butler

Baylor Scott & White Health, Dallas (United States of America)

3 More presentations in this session

Presentation thumbnail
Welcome and introduction.
Professor A. Stewart Coats (Sydney, AU)
Slides Video
Presentation thumbnail
Using empagliflozin for HFpEF treatment - what does this look like in practice?
Doctor S. Zieroth (Winnipeg, CA)
Slides Video
Presentation thumbnail
Panel discussion and close.
Professor A. Stewart Coats (Sydney, AU)
Slides Video

Access the full session

Session thumbnail
A new era for HFpEF – Exploring the role of empagliflozin in practice
Video

The Event

Event poster

Heart Failure 2022

22 May 2022 15:00 CET
You may be interested in
thumbnail
Congress Presentation
What is the evidence for empagliflozin in HFpEF?
27 August 2022
thumbnail
Congress Presentation
EMPEROR - Empagliflozin in Patients with Chronic Heart Failure
25 August 2023
thumbnail
Congress Session
Clinical trial updates on heart failure
25 August 2023
thumbnail
Congress Presentation
Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction results from the EMPULSE trial.
23 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources